JP2019516407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516407A5 JP2019516407A5 JP2019512944A JP2019512944A JP2019516407A5 JP 2019516407 A5 JP2019516407 A5 JP 2019516407A5 JP 2019512944 A JP2019512944 A JP 2019512944A JP 2019512944 A JP2019512944 A JP 2019512944A JP 2019516407 A5 JP2019516407 A5 JP 2019516407A5
- Authority
- JP
- Japan
- Prior art keywords
- biomarkers
- biomarker
- sample
- expression
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims description 242
- 230000014509 gene expression Effects 0.000 claims description 132
- 238000000034 method Methods 0.000 claims description 127
- 108020004707 nucleic acids Proteins 0.000 claims description 124
- 150000007523 nucleic acids Chemical class 0.000 claims description 124
- 102000039446 nucleic acids Human genes 0.000 claims description 124
- 208000009956 adenocarcinoma Diseases 0.000 claims description 64
- 210000001519 tissue Anatomy 0.000 claims description 42
- 210000004072 lung Anatomy 0.000 claims description 41
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 33
- 201000005202 lung cancer Diseases 0.000 claims description 33
- 208000020816 lung neoplasm Diseases 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 238000003556 assay Methods 0.000 claims description 22
- 210000001124 body fluid Anatomy 0.000 claims description 22
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 20
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 20
- 239000010839 body fluid Substances 0.000 claims description 20
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 20
- 238000004458 analytical method Methods 0.000 claims description 16
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 16
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 13
- 238000003559 RNA-seq method Methods 0.000 claims description 13
- 238000010240 RT-PCR analysis Methods 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 13
- 238000012896 Statistical algorithm Methods 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 238000009396 hybridization Methods 0.000 claims description 12
- 238000012163 sequencing technique Methods 0.000 claims description 12
- 206010036790 Productive cough Diseases 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- 210000001808 exosome Anatomy 0.000 claims description 11
- 230000002757 inflammatory effect Effects 0.000 claims description 11
- 210000003296 saliva Anatomy 0.000 claims description 11
- 210000003802 sputum Anatomy 0.000 claims description 11
- 208000024794 sputum Diseases 0.000 claims description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 11
- 210000002700 urine Anatomy 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 10
- 239000012188 paraffin wax Substances 0.000 claims description 10
- 239000008188 pellet Substances 0.000 claims description 10
- 108010050904 Interferons Proteins 0.000 claims description 9
- 230000003321 amplification Effects 0.000 claims description 9
- 238000009169 immunotherapy Methods 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 238000000636 Northern blotting Methods 0.000 claims description 8
- 101710163270 Nuclease Proteins 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 238000003633 gene expression assay Methods 0.000 claims description 8
- 238000002493 microarray Methods 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 235000002020 sage Nutrition 0.000 claims description 8
- 239000003155 DNA primer Substances 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 7
- 239000002955 immunomodulating agent Substances 0.000 claims description 7
- 230000000241 respiratory effect Effects 0.000 claims description 7
- 102000014150 Interferons Human genes 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 6
- 238000010562 histological examination Methods 0.000 claims description 6
- 210000002865 immune cell Anatomy 0.000 claims description 6
- 229940079322 interferon Drugs 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 4
- 229960005386 ipilimumab Drugs 0.000 claims description 4
- 229960003301 nivolumab Drugs 0.000 claims description 4
- 229960002621 pembrolizumab Drugs 0.000 claims description 4
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000003044 adaptive effect Effects 0.000 claims description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000010195 expression analysis Methods 0.000 claims description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 33
- 239000003814 drug Substances 0.000 claims 30
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662337591P | 2016-05-17 | 2016-05-17 | |
| US201662337645P | 2016-05-17 | 2016-05-17 | |
| US62/337,645 | 2016-05-17 | ||
| US62/337,591 | 2016-05-17 | ||
| US201662396587P | 2016-09-19 | 2016-09-19 | |
| US62/396,587 | 2016-09-19 | ||
| US201662420836P | 2016-11-11 | 2016-11-11 | |
| US62/420,836 | 2016-11-11 | ||
| US201662425717P | 2016-11-23 | 2016-11-23 | |
| US62/425,717 | 2016-11-23 | ||
| PCT/US2017/033110 WO2017201165A1 (en) | 2016-05-17 | 2017-05-17 | Methods for subtyping of lung adenocarcinoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516407A JP2019516407A (ja) | 2019-06-20 |
| JP2019516407A5 true JP2019516407A5 (enExample) | 2020-07-02 |
| JP7241353B2 JP7241353B2 (ja) | 2023-03-17 |
Family
ID=60326094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512944A Active JP7241353B2 (ja) | 2016-05-17 | 2017-05-17 | 肺腺癌のサブタイピングのための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10934595B2 (enExample) |
| EP (1) | EP3458612B1 (enExample) |
| JP (1) | JP7241353B2 (enExample) |
| CN (2) | CN116987790A (enExample) |
| CA (1) | CA3024747A1 (enExample) |
| WO (1) | WO2017201165A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3149209B1 (en) | 2014-05-30 | 2021-02-17 | Genecentric Therapeutics, Inc. | Methods for typing of lung cancer |
| US10934595B2 (en) | 2016-05-17 | 2021-03-02 | Genecentric Therapeutics, Inc. | Methods for subtyping of lung adenocarcinoma |
| CA3024744A1 (en) | 2016-05-17 | 2017-11-23 | Genecentric Therapeutics, Inc. | Methods for subtyping of lung squamous cell carcinoma |
| EP4628895A3 (en) * | 2017-01-13 | 2025-12-17 | Mayo Foundation for Medical Education and Research | Materials and methods for treating cancer |
| KR102802863B1 (ko) * | 2017-12-01 | 2025-04-30 | 일루미나, 인코포레이티드 | 약물 효능을 평가하기 위한 시스템 및 방법 |
| US12266426B2 (en) | 2017-12-01 | 2025-04-01 | Illumina, Inc. | Method for administering a cancer treatment |
| US12195805B2 (en) | 2018-02-13 | 2025-01-14 | Genecentric Therapeutics, Inc. | Methods for subtyping of bladder cancer |
| US11414698B2 (en) * | 2018-03-22 | 2022-08-16 | Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi | Method of quantifying mutant allele burden of target gene |
| CA3105292A1 (en) * | 2018-08-10 | 2020-02-13 | Omniseq, Inc. | Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade |
| WO2020076897A1 (en) | 2018-10-09 | 2020-04-16 | Genecentric Therapeutics, Inc. | Detecting cancer cell of origin |
| WO2020081463A1 (en) * | 2018-10-18 | 2020-04-23 | Verily Life Sciences Llc | Systems and methods for using image processing to generate inferences of biomarker for immunotherapy |
| CN112442535A (zh) * | 2019-08-27 | 2021-03-05 | 上海善准生物科技有限公司 | 原发性肺腺癌分子分型及生存风险基因群及诊断产品和应用 |
| BR112022004952A2 (pt) * | 2019-10-11 | 2022-06-28 | Bioventures Llc | Uso de detecção simultânea de marcadores para avaliação de glioma difuso e capacidade de resposta a tratamento |
| CN112034185A (zh) * | 2020-09-11 | 2020-12-04 | 上海市胸科医院 | Gpr110、vegfr、cd34在鉴别肺腺癌亚型中的用途 |
| CN112530595A (zh) * | 2020-12-21 | 2021-03-19 | 无锡市第二人民医院 | 一种基于多分支链式神经网络的心血管疾病分类方法和装置 |
| US20240182984A1 (en) * | 2021-03-30 | 2024-06-06 | Genecentric Therapeutics, Inc. | Methods for assessing proliferation and anti-folate therapeutic response |
| CN113687076B (zh) * | 2021-07-14 | 2024-03-01 | 郑州大学 | 一种可用于肺腺癌早期诊断的联合检测血清标志物及其应用 |
| WO2023010327A1 (zh) * | 2021-08-04 | 2023-02-09 | 杭州浙大迪迅生物基因工程有限公司 | 一种人白三烯受体CysLTR2 mRNA RT-PCR检测用引物探针组和试剂盒 |
| CN113903400B (zh) * | 2021-10-29 | 2024-10-01 | 复旦大学附属华山医院 | 免疫相关疾病分子分型和亚型分类器的分类方法、系统 |
| CN113981093B (zh) * | 2021-11-26 | 2023-06-16 | 大连医科大学附属第一医院 | Inpp4b基因表达量的检测剂在制备用于预测肺腺癌放疗敏感性的试剂盒的应用 |
| CN114480644A (zh) * | 2022-01-07 | 2022-05-13 | 深圳市龙华区人民医院 | 肺腺癌基于代谢基因的分子分型 |
| CN114574589B (zh) * | 2022-04-28 | 2022-08-16 | 深圳市第二人民医院(深圳市转化医学研究院) | 标志物znf207在制备肺腺癌诊断试剂中的应用及诊断试剂盒 |
| US20250327132A1 (en) * | 2022-06-13 | 2025-10-23 | The Government of the United States, as represented by the Director of the Defense Health Agency | Lung Cancer-Related Biomarkers and Methods of Using the Same |
| CN115896282A (zh) * | 2022-08-02 | 2023-04-04 | 上海市同仁医院 | 一种对甲状腺微小乳头状癌进行分子分型的方法以及分子标志物应用 |
| CN115862876B (zh) * | 2023-03-02 | 2023-05-26 | 北京师范大学 | 基于免疫微环境基因群预测肺腺癌患者预后的装置 |
| CN116403648B (zh) * | 2023-06-06 | 2023-08-01 | 中国医学科学院肿瘤医院 | 一种基于多维分析建立的小细胞肺癌免疫新分型方法 |
| CN117491636A (zh) * | 2023-11-21 | 2024-02-02 | 郑州大学 | 一种用于肺癌诊断的生物标志物及其应用 |
| CN117635612A (zh) * | 2024-01-25 | 2024-03-01 | 天津博思特医疗科技有限责任公司 | 一种肺部ct图像的识别方法 |
| CN118460691B (zh) * | 2024-07-11 | 2024-10-15 | 浙江省血液中心 | 用于hla基因多重扩增的引物组合物、应用和基因分型方法 |
| CN119876392B (zh) * | 2025-01-06 | 2025-08-12 | 上海市第六人民医院 | 一种用于辅助诊断肺腺癌骨转移的生物标志物 |
| CN120445960A (zh) * | 2025-05-07 | 2025-08-08 | 广州医科大学附属第一医院（广州呼吸中心） | 一种外泌体表面标志物鉴别乳腺癌亚型的方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| CA2118806A1 (en) | 1991-09-18 | 1993-04-01 | William J. Dower | Method of synthesizing diverse collections of oligomers |
| AU675054B2 (en) | 1991-11-22 | 1997-01-23 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| DE69829402T2 (de) | 1997-10-31 | 2006-04-13 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | Expressionsprofile in adulten und fötalen organen |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| US6670321B1 (en) | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
| AU2002226912A1 (en) | 2000-11-16 | 2002-05-27 | Cedars-Sinai Medical Center | Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| AU2002343443A1 (en) | 2001-09-28 | 2003-04-14 | Whitehead Institute For Biomedical Research | Classification of lung carcinomas using gene expression analysis |
| US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| JP2007006792A (ja) * | 2005-06-30 | 2007-01-18 | Hitachi Software Eng Co Ltd | 肺腺癌の胸膜浸潤を判別するための遺伝子セット |
| WO2008151110A2 (en) | 2007-06-01 | 2008-12-11 | The University Of North Carolina At Chapel Hill | Molecular diagnosis and typing of lung cancer variants |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| CA2726531A1 (en) * | 2008-06-05 | 2009-12-10 | University Health Network | Compositions and methods for classifying lung cancer and prognosing lung cancer survival |
| CN101509035A (zh) | 2008-09-05 | 2009-08-19 | 中国人民解放军总医院 | 肺癌分型的基因序列及其应用 |
| WO2013172926A1 (en) | 2012-05-14 | 2013-11-21 | Yale University | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer |
| WO2013192089A1 (en) | 2012-06-18 | 2013-12-27 | The University Of North Carolina At Chapel Hill | Methods for head and neck cancer prognosis |
| EP2806274A1 (en) | 2013-05-24 | 2014-11-26 | AIT Austrian Institute of Technology GmbH | Lung cancer diagnostic method and means |
| US20150057335A1 (en) * | 2013-08-20 | 2015-02-26 | National Cancer Center | Novel fusion genes identified in lung cancer |
| EP3603748A1 (en) * | 2014-05-13 | 2020-02-05 | MedImmune Limited | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer |
| US9885721B2 (en) * | 2014-05-29 | 2018-02-06 | Spring Bioscience Corporation | PD-L1 antibodies and uses thereof |
| EP3149209B1 (en) | 2014-05-30 | 2021-02-17 | Genecentric Therapeutics, Inc. | Methods for typing of lung cancer |
| MX389663B (es) * | 2014-10-14 | 2025-03-20 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas. |
| CN107849613A (zh) | 2015-04-14 | 2018-03-27 | 基因中心治疗公司 | 用于肺癌分型的方法 |
| US10934595B2 (en) | 2016-05-17 | 2021-03-02 | Genecentric Therapeutics, Inc. | Methods for subtyping of lung adenocarcinoma |
| CA3024744A1 (en) | 2016-05-17 | 2017-11-23 | Genecentric Therapeutics, Inc. | Methods for subtyping of lung squamous cell carcinoma |
| WO2019018764A1 (en) * | 2017-07-21 | 2019-01-24 | Genecentric Therapeutics, Inc. | METHODS OF DETERMINING RESPONSE TO PARP INHIBITORS |
-
2017
- 2017-05-17 US US16/302,167 patent/US10934595B2/en active Active
- 2017-05-17 CN CN202310993898.6A patent/CN116987790A/zh active Pending
- 2017-05-17 CN CN201780044229.7A patent/CN109790583B/zh active Active
- 2017-05-17 CA CA3024747A patent/CA3024747A1/en active Pending
- 2017-05-17 EP EP17800091.5A patent/EP3458612B1/en active Active
- 2017-05-17 JP JP2019512944A patent/JP7241353B2/ja active Active
- 2017-05-17 WO PCT/US2017/033110 patent/WO2017201165A1/en not_active Ceased
-
2021
- 2021-01-22 US US17/156,024 patent/US12139763B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516407A5 (enExample) | ||
| JP2019516406A5 (enExample) | ||
| JP7241353B2 (ja) | 肺腺癌のサブタイピングのための方法 | |
| ES2536233T3 (es) | Predicción de pronóstico para aplicación relacionada con cáncer colorrectal | |
| CN107532214B (zh) | 用于败血症诊断的方法 | |
| JP7241352B2 (ja) | 肺扁平上皮癌のサブタイピングのための方法 | |
| JP6144695B2 (ja) | タキサン療法を用いて乳癌を処置する方法 | |
| US10196691B2 (en) | Colon cancer gene expression signatures and methods of use | |
| JP6039656B2 (ja) | 癌再発の予後予測のための方法および装置 | |
| US10113201B2 (en) | Methods and compositions for diagnosis of glioblastoma or a subtype thereof | |
| JP6285009B2 (ja) | 前立腺ガンの予後の検知及び判定のための組成物及び該検知及び判定方法 | |
| US20160024595A1 (en) | Characterization of melanoma using a molecular signature | |
| JP2016505247A5 (enExample) | ||
| EP1721159B1 (en) | Breast cancer prognostics | |
| EP3472361A1 (en) | Compositions and methods for diagnosing lung cancers using gene expression profiles | |
| US20250137066A1 (en) | Compostions and methods for diagnosing lung cancers using gene expression profiles | |
| EP2333112B1 (en) | Breast cancer prognostics | |
| WO2015179777A2 (en) | Gene expression profiles associated with sub-clinical kidney transplant rejection | |
| WO2019018764A1 (en) | METHODS OF DETERMINING RESPONSE TO PARP INHIBITORS | |
| WO2011153345A2 (en) | A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients | |
| WO2018160880A1 (en) | Compositions and methods for detecting sessile serrated adenomas/polyps | |
| CN111315897B (zh) | 用于黑素瘤检测的方法 | |
| US20240182984A1 (en) | Methods for assessing proliferation and anti-folate therapeutic response | |
| CN110129444A (zh) | 一种检测放射性损伤的试剂及其应用 | |
| CN114901836B (zh) | 肝移植的临床和分子预后标志物 |